Danaher Corp
Close on Oct 30, 2026Market cap $163.25BP/E 41.2Yield –
Danaher Consolidated Recurring Revenue by Quarter
Consolidated Recurring Revenue (Consumables, Reagents, Services & OTL Leases) ($M)
Danaher Consolidated Recurring Revenue: $5,399M in Q3 2026, up 7.6% from a year earlier. That is the highest of the 15 quarters on record here.
Where the Q3 2026 figure comes from
Source: Danaher SEC 10-Q (2026Q3, filed 2026-10-21) ↗
2-dimensional revenue breakdown in Revenue Disclosures (Note 3 / Note 6, continuing operations basis following the Veralto spin-off); Q4 is calculated as Full Year (10-K) minus 9-month (10-Q Q3). Represents ~83% of Danaher's total revenue in Q3 2026 ($5.021M / $6.053M).
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
Breakdown
What makes up consolidated Recurring Revenue
- Biotechnology — Recurring Revenue (Recurring: Chromatography Resins, Filtration Membranes, Cell Culture Media)1,584 · Q3 2026
- Life Sciences — Recurring Revenue (Recurring: Abcam Antibodies, IDT Genes, Chromatography Columns, Services)1,282 · Q3 2026
- Diagnostics — Recurring Revenue (Recurring: Cepheid Test Cartridges, Beckman/Radiometer Reagents, Masimo Sensors)2,533 · Q3 2026
Cite this data
StockData. (2026). Danaher Consolidated Recurring Revenue ($M), quarterly Q1 2023–Q3 2026 [Data set]. Compiled from Danaher SEC filings and investor materials. https://stockdatahq.com/stocks/dhr/kpis/disagg-total-type-recurring
See every metric in the Danaher KPI table. Data updated Nov 2, 2026.